| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 10/05/1999 | US5962265 A polypeptide is described which is expressed at a particularly high level in tissues of the human immune system. |
| 10/05/1999 | US5962261 Polynucleotides encoding a neuronal extracellular matrix protein |
| 10/05/1999 | US5962260 Recombinant production of human and bovine receptors for modified low-density lipoprotein |
| 10/05/1999 | US5962259 Response regulator polynucleotides |
| 10/05/1999 | US5962256 Nuclear thyroid hormone receptor-interacting polynucleotides and related molecules and methods |
| 10/05/1999 | US5962245 Methods for detecting the presence of advanced glycosylation endproducts |
| 10/05/1999 | US5962243 Assaying for presence of farnesyl protein transferase activity in an enzyme composition by determining transfer of moiety to k-rasb protein or k-rasb peptide having farnesyl acceptor |
| 10/05/1999 | US5962240 Mycobacterium proteins and applications |
| 10/05/1999 | US5962236 Immunoassay using antibodies against free lysyl pyridinoline cross-links in unhydrolyzed urine sample |
| 10/05/1999 | US5962232 Protein kinase molecules |
| 10/05/1999 | US5962231 Human glutathione-S-transferase |
| 10/05/1999 | US5962230 Diagnosis and treatment of glaucoma |
| 10/05/1999 | US5962226 Human RNA-binding protein |
| 10/05/1999 | US5962224 Isolated DNA encoding p62 polypeptides and uses therefor |
| 10/05/1999 | US5962220 St receptor binding moieties bind to the st receptor which is found on human colon cells. the invention relates to antisense compositions specifically targeted to colon cells. |
| 10/05/1999 | US5962217 MSRV1 virus and MSRV2 pathogen and/or infective agent associated with multiple sclerosis, and biopolymer constituents thereof |
| 10/05/1999 | US5962216 Tumor-activated prodrug compounds and treatment |
| 10/05/1999 | US5962026 Solid compositions of fibrin monomer |
| 10/05/1999 | US5962025 Administering collagen |
| 10/05/1999 | US5962019 Alkanol solvent of from 2 to 3 carbon atoms in combination with at least one non-ionic surfactant. |
| 10/05/1999 | US5962017 Pharmaceutical compositions comprising cyclosporins |
| 10/05/1999 | US5962014 Hydrophilic component other than the hydrophilic surfactant, lipophilic component and hydrophilic surfactant other than the hydrophilic component; upon dilution with water an oil-in-water microemulsion is formed. |
| 10/05/1999 | US5961985 Vaccine and serum for endotoxin associated disease immunization and treatment, detoxified endotoxin, and bacterial mutant |
| 10/05/1999 | US5961980 Bowman-birk inhibitor compositions and methods for the treatment of genitourinary diseases |
| 10/05/1999 | US5961978 Therapeutically useful peptides and peptide fragments |
| 10/05/1999 | US5961977 Orally administering an autoantigen |
| 10/05/1999 | US5961976 Monoclonal antibodies characterized by their ability to neutralize in vitro and in vivo primary isolates of human immunodeficiency virus (hiv) and related immunodeficiency viruses. |
| 10/05/1999 | US5961974 This invention provides isolated human and murine cd40-l polypeptides that bind to the extracellular binding region of a cd40 receptor. the present invention relates to a novel cytokine. |
| 10/05/1999 | US5961973 Binding agent which specifically binds a surface component of a pathogen, for instance the gp120 viral coat protein of the human immunodeficiency virus, and a catalytic moiety |
| 10/05/1999 | US5961969 Enhancing natural killer cell cytotoxicity. |
| 10/05/1999 | US5961954 Chealators of type XN1 S1 X1 for radioactive isotopes, their metal complexes and their diagnostic and therapeutical uses |
| 10/05/1999 | US5960792 Device for aerosolized delivery of peptide drugs |
| 10/05/1999 | CA2173544C Use of a least one 6"-substituted pyrimidine derivative in a composition as a cyclooxygenase activator and/or stabilizer |
| 10/05/1999 | CA2161962C Adenovirus vectors for gene therapy |
| 10/05/1999 | CA2111336C Broad spectrum antimicrobial compounds and methods of use |
| 10/01/1999 | CA2249043A1 Novel compounds |
| 10/01/1999 | CA2227508A1 Paip, a novel human protein which bridges the 3' and 5' end of mrna, and use thereof as a target for translational modulation to treat human disease |
| 09/30/1999 | WO1999049065A1 Antisense modulation of human mdm2 expression |
| 09/30/1999 | WO1999049060A1 Use of growth hormone binding protein with a nuclear localization sequence (nls-ghbp) |
| 09/30/1999 | WO1999049055A1 Human casb12 polypeptide, a serine protease |
| 09/30/1999 | WO1999049049A1 Streptococcus sag-a, a structural protein associated with sls activity |
| 09/30/1999 | WO1999049042A1 HUMAN Rad1 CELL CYCLE CHECKPOINT |
| 09/30/1999 | WO1999049041A1 Drm, a secreted protein with cell growth inhibiting activity, and related methods and compositions |
| 09/30/1999 | WO1999049040A1 HUMAN G-PROTEIN COUPLED RECEPTOR GPR6sb |
| 09/30/1999 | WO1999049038A2 Human calcium-binding proteins |
| 09/30/1999 | WO1999049037A2 Protein phosphatase-related molecules |
| 09/30/1999 | WO1999049034A1 Breast cancer antigen |
| 09/30/1999 | WO1999049033A1 Casb414: antigen overexpressed in several tumors |
| 09/30/1999 | WO1999049031A1 Use of nucleic acid molecules as antiviral agents |
| 09/30/1999 | WO1999049030A1 Compounds related to pap-1 |
| 09/30/1999 | WO1999049027A1 Methods for prevention and treatment of cancer |
| 09/30/1999 | WO1999049025A2 Human vault rna |
| 09/30/1999 | WO1999049023A1 The cytokine family member 2-21 |
| 09/30/1999 | WO1999049019A2 Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics |
| 09/30/1999 | WO1999049018A1 Glycosyl sulfotransferase-3 |
| 09/30/1999 | WO1999049015A2 Cardiac-derived stem cells |
| 09/30/1999 | WO1999048925A1 Methods for identifying inducers and inhibitors of proteolytic antibodies, compositions and their uses |
| 09/30/1999 | WO1999048924A1 Endostatin derived peptides with anti-angiogenic and anti-cancer activity |
| 09/30/1999 | WO1999048923A1 Multivalent ligands which modulate angiogenesis |
| 09/30/1999 | WO1999048920A1 Novel physiologically active peptides and utilization thereof |
| 09/30/1999 | WO1999048917A2 Formulation having a papilloma virus-specific protein, and the production and use thereof |
| 09/30/1999 | WO1999048915A1 Orphan nuclear receptor |
| 09/30/1999 | WO1999048911A1 Monobactam enzyme inhibitors |
| 09/30/1999 | WO1999048910A1 Use of inhibitors of mammalian asparaginyl endopeptidase for therapy of autoimmune disease |
| 09/30/1999 | WO1999048906A1 Antisense oligonucleotide modulation of human her-2 expression |
| 09/30/1999 | WO1999048904A1 HIGH AFFINITY TGFβ NUCLEIC ACID LIGANDS AND INHIBITORS |
| 09/30/1999 | WO1999048537A1 Use of scatter factor to enhance angiogenesis |
| 09/30/1999 | WO1999048536A2 Delivery of long lasting therapeutic agents by forming covalent attachments in vivo |
| 09/30/1999 | WO1999048535A1 Formulations for protection of peg-interferon alpha conjugates |
| 09/30/1999 | WO1999048528A1 Vascularization inhibitors |
| 09/30/1999 | WO1999048527A1 Apo-2 ligand-anti-her-2 antibody synergism |
| 09/30/1999 | WO1999048526A1 METHOD OF RENDERING A HUMAN IMMUNODEFICIENCY VIRUS POPULATION REPLICATION INCOMPETENT $i(IN VIVO) |
| 09/30/1999 | WO1999048523A2 Antagonists of the inflammatory mediator oncostatin m (osm) |
| 09/30/1999 | WO1999048522A1 Pharmaceutical composition containing a cysteine protease inhibitor for prophylaxis and therapy of brain tissue impairment |
| 09/30/1999 | WO1999048521A1 Sciellin and uses thereof |
| 09/30/1999 | WO1999048520A1 Novel preparation of protracted acting human insulin |
| 09/30/1999 | WO1999048519A1 Sustained-release preparation of physiologically active polypeptide and production thereof |
| 09/30/1999 | WO1999048518A2 Medicament for preventing or treating papilloma virus-specific tumors |
| 09/30/1999 | WO1999048517A1 Pharmaceutical compositions for prolonged peptide release and preparation method |
| 09/30/1999 | WO1999048516A1 Utilization of gelatine hydrolizats |
| 09/30/1999 | WO1999048515A1 Trimeric antigenic o-linked glycopeptide conjugates, methods of preparation and uses thereof |
| 09/30/1999 | WO1999048514A1 Methods and materials for treating inflammatory diseases |
| 09/30/1999 | WO1999048513A1 Methods and compositions for peptide synthesis |
| 09/30/1999 | WO1999048512A1 Use of at least one protein extract of the moringa genus plant seeds and corresponding cosmetic and/or pharmacological composition |
| 09/30/1999 | WO1999048508A1 Treatment of ulcerative colitis with tropomyosin isoforms and monoclonal antibodies to tropomyosin isoforms |
| 09/30/1999 | WO1999048478A1 Use of glycosaminoglycans degrading enzymes for management of airway associated diseases |
| 09/30/1999 | WO1999048470A1 Glycylglycine oleamide in dermo-cosmetology |
| 09/30/1999 | WO1999048348A1 Helicobacter pylori derived factor which inhibits ena-78 secretion |
| 09/30/1999 | WO1999042478A3 LEPTOSPIRAL OUTER MEMBRANE PROTEIN, LipL32 |
| 09/30/1999 | WO1999041387A3 Prostate-associated serine protease |
| 09/30/1999 | WO1999040945A3 Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery |
| 09/30/1999 | WO1999040198A3 Identification, production and use of staphylokinase derivatives with reduced immunogenicity and/or reduced clearance |
| 09/30/1999 | WO1999040107A3 Method of promoting keratinocyte proliferation |
| 09/30/1999 | WO1999039743A3 Method of promoting hepatic cell proliferation |
| 09/30/1999 | WO1999039741A3 Systemic delivery of serum stable plasmid lipid particles for cancer therapy |
| 09/30/1999 | WO1999038987A8 METHOD FOR PRODUCING, BY PLANT CELLS, α1-ANTITRYPSIN AND ITS ALLELES, AND PRODUCTS CONTAINING THE RESULTING α1-ANTITRYPSIN |
| 09/30/1999 | WO1999038495A3 Controlled release delivery of peptide or protein |
| 09/30/1999 | WO1999037788A3 Diagnosis and treatment of aur1 and/or aur2 related disorders |
| 09/30/1999 | WO1999037777A3 Differentiation-associated sequences and methods of use therefor |
| 09/30/1999 | WO1999037337A3 Prostheses with associated growth factors |